Compare GLOO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLOO | LYEL |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 512.5M | 504.8M |
| IPO Year | 2025 | 2021 |
| Metric | GLOO | LYEL |
|---|---|---|
| Price | $6.13 | $25.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $13.75 | ★ $25.00 |
| AVG Volume (30 Days) | 79.7K | ★ 113.7K |
| Earning Date | 12-17-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,523,000.00 | $41,000.00 |
| Revenue This Year | $407.93 | N/A |
| Revenue Next Year | $81.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 217.17 | N/A |
| 52 Week Low | $5.30 | $7.65 |
| 52 Week High | $9.98 | $45.00 |
| Indicator | GLOO | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 45.82 |
| Support Level | $5.99 | $24.57 |
| Resistance Level | $6.74 | $27.89 |
| Average True Range (ATR) | 0.59 | 1.68 |
| MACD | 0.07 | -0.11 |
| Stochastic Oscillator | 37.50 | 51.36 |
Gloo Holdings Inc is engaged in building a technology platform company. It has provided a breadth of products, services, and solutions to the two primary stakeholders at the core of the faith and flourishing ecosystem: (1) network capability providers (NCPs) and (2) the churches and frontline organizations (CFLs) it serves. The company serves as a digital infrastructure between NCPs and CFLs. By facilitating efficient exchange between the two, Gloo enables both sides to succeed; CFLs gain access to resources and NCPs benefit from efficient distribution and targeted reach. This creates a virtuous cycle, strengthening the platform with each interaction. The Gloo platform includes a suite of technology, marketplace, and service solutions offered directly from Gloo or from Gloo's subsidiaries.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.